A melanoma univariate prognosis analysis revealed that patients with HSPG2 mutations presented a significantly more prolonged outcome than HSPG2 wild-type patients (median survival time: 49.3 vs. 25.7 months, Log–rank test p = 0.012; Figure 2A). The gene discussed is HSPG2; the disease is melanoma.